Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03277989 · ClinicalTrials.gov registry record
INFINITY™Total Ankle Replacement Follow-up
A clinical trial, sponsored by Stryker Trauma and Extremities.
- Terminated
- Registry status
- 155
- Enrollment target
NCT03277989: Clinical Trial study, sponsored by Stryker Trauma and Extremities.
NCT03277989 is a clinical trial that was terminated before completion, run by Stryker Trauma and Extremities. The registered enrollment target is 155 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03277989 was terminated before completion, sponsored by Stryker Trauma and Extremities.
- TERMINATED
- Registry status
- 155 participants
- Enrollment target
Study Summary
Study Title INFINITY™Total Ankle Replacement Follow-up (ITAR) Study Design Prospective, multi-site, multi-year post-market clinical follow-up study Study Group Primary/Unilateral and/or bilateral Total Ankle Arthroplasty subjects implanted with INFINITY™ Total Ankle System Number of Subjects 150 with 9 sites
Primary Outcome
The primary endpoint is a survivorship rate at 10 years as defined with a Kaplan Meier survivorship analysis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2017-10-09 |
| Est. Completion | 2023-03-31 |
Why NCT03277989 stopped before completion
NCT03277989 is an observational study that tracks outcomes without assigning an intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03277989 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03277989 about?
NCT03277989 is a clinical study titled "INFINITY™Total Ankle Replacement Follow-up". Study Title INFINITY™Total Ankle Replacement Follow-up (ITAR) Study Design Prospective, multi-site, multi-year post-market clinical follow-up study Study Group Primary/Unilateral and/or bilateral Total Ankle Arthroplasty subjects implanted with INFINITY™ Total Ankle System Number of Subjects 150 wit...
What is the current status of trial NCT03277989?
This trial is currently terminated. The enrollment target is 155 participants. The study started on 2017-10-09. Estimated completion is 2023-03-31.
Who is sponsoring clinical trial NCT03277989?
This trial is sponsored by Stryker Trauma and Extremities, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI